Eye Journal
Intravitreal aflibercept for choroidal neovascularisation in angioid streaks – (Eye 29, 1236 (September 2015))
Intravitreal aflibercept for choroidal neovascularisation in angioid streaks Eye 29, 1236 (September 2015). doi:10.1038/eye.2015.92 Authors: S Vaz-Pereira, L Collaço, G De Salvo & P van Zeller
Factors influencing the outcome of polypoidal choroidal vasculopathy following combined treatment with photodynamic therapy and intravitreal ranibizumab – (Eye 29, 1238 (September 2015))
Factors influencing the outcome of polypoidal choroidal vasculopathy following combined treatment with photodynamic therapy and intravitreal ranibizumab Eye 29, 1238 (September 2015). doi:10.1038/eye.2015.101 Authors: C S Tan, W K Ngo, L W Lim & T H Lim
Reply to ‘Factors influencing the outcome of polypoidal choroidal vasculopathy following combined treatment with photodynamic therapy and intravitreal ranibizumab’ – (Eye 29, 1239 (September 2015))
Reply to ‘Factors influencing the outcome of polypoidal choroidal vasculopathy following combined treatment with photodynamic therapy and intravitreal ranibizumab’ Eye 29, 1239 (September 2015). doi:10.1038/eye.2015.102 Authors: M Ho, E C Lo, A L Young & D T L Liu
Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants – (Eye 29, 1240 (September 2015))
Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants Eye 29, 1240 (September 2015). doi:10.1038/eye.2015.145 Authors: Y Yang, C Bailey, F G Holz, N Eter, M Weber, C Baker, S Kiss, U Menchini, J M Ruiz Moreno, P Dugel & A Lotery
A review of therapies for diabetic macular oedema and rationale for combination therapy – (Eye 29, 1115 (September 2015))
A review of therapies for diabetic macular oedema and rationale for combination therapy Eye 29, 1115 (September 2015). doi:10.1038/eye.2015.110 Authors: W M K Amoaku, S Saker & E A Stewart